Elevated Serum Creatine Kinase During the Treatment of Patients with Graves’ Disease with Antithyroid Drugs: New Insights into an Old Issue

Abstract

Serum creatine kinase (CK) elevation can occur in some patients with Graves’ disease treated with antithyroid drugs (ATDs). This study retrospectively investigated clinical characteristics and biochemical data of patients with Graves’ disease who experienced serum CK elevation during ATD treatment. CK elevation was observed in 29.6% (37/125) of patients, with 11.2% (14/125) being symptomatic. This incidence is higher than previously reported (13.5%). There were no differences in pre-treatment characteristics between patients with and without CK elevation. The intervals between the initiation of ATD treatment or normalization of thyroid function and the onset of CK elevation were 11.3±8.0 and 5.8±6.6 weeks, respectively, and peak serum CK levels averaged 441.9±394.0 IU/l. Markedly elevated serum CK were accompanied by increased serum myoglobin levels. Serum CK elevation occurred either continuously or intermittently, or as a single episode during the course of treatment. Thyroid function at the time of CK elevation varied from hyperthyroid to normal to hypothyroid. In conclusion, serum CK elevation in patients with Graves’ disease treated with ATDs is not uncommon, with symptomatic cases accounting for approximately 10%, and the frequency increasing to around 30% when asymptomatic cases are included. The characteristics observed in our patients suggest the involvement of alternative, as yet unknown mechanisms beyond the relative hypothyroidism theory and the ATD side-effect theory in the development of CK elevation during ATD treatment in patients with Graves’ disease.

Keywords

myoglobin - muscle - treatment

Publication History

Received: 23 April 2025

Accepted after revision: 07 July 2025

Article published online:
28 July 2025

• References

• 1 Suzuki S, Ichikawa K, Nagai M. et al. Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to Graves disease. A novel side effect of antithyroid drugs. Arch Intern Med 1997; 157: 693-696
• 2 Mizuno H, Sugiyama Y, Nishi Y. et al. Elevation of serum creatine kinase in response to medical treatment of Graves’ disease in children. Acta Paediat 2006; 95: 243-245
• 3 Ito T, Katahira M, Hanakita M. et al. A case of elevation of serum creatine kinase with antithyroid medications for Graves’ disease. J Endocrinol Metab 2012; 2: 244-247
• 4 Lim AY, Kek PC, Soh AW. Carbimazole-induced myositis in the treatment of Graves’ disease: a complication in genetically susceptible individuals?. Singapore Med J 2013; 54: e133-e136
• 5 Tsang CC, Hui WS, Lo KM. et al. Anti-thyroid drugs-related myopathy: is carbimazole the real culprit?. Int J Endocrinol Metab 2015; 13: e17570
• 6 Uçan B, Yüksek C, Kizilgul M. et al. Creatine kinase elevation during antithyroid treatment of a patient with Graves’ disease: a case report and review of literature. Exp Clin Endocrinol Diabet Rep 2016; 02: e14-e16
• 7 Bou Khalil R, Abou Salbi M, Sissi S. et al. Methimazole-induced myositis: a case report and review of the literature. Endocrinol Diabetes Metab Case Rep. 2013: 130008
• 8 Kim H, Kim J, Huh R. et al. Elevation of serum creatine kinase during methimazole treatment of Graves disease in a 13-year-old girl and a literature review of similar cases. Ann Pediatr Endocrinol Metab 2015; 20: 106-109
• 9 Li Q, Liu Y, Zhang Q. et al. Myopathy in hyperthyroidism as a consequence of rapid reduction of thyroid hormone: a case report. Medicine (Baltimore) 2017; 96: e7591
• 10 Lu R, Wang H, Hong T. et al. Myopathy after rapid correction of hyperthyroidism: a case report and review of literature. Medicine (Baltimore) 2020; 99: e18878
• 11 Ji YK, Kim SH. Myopathy Associated with Treatment of Graves’ Disease. Medicina (Kaunas) 2021; 57: 1016
• 12 O’Donnell N, McCarthy A, Thong K. Carbimazole induced rhabdomyolysis. Endocrinol Diabetes Metab Case Rep 2021; 21-0006
• 13 Si Y, Su F, Wu H. et al. Elevation of serum creatine kinase induced by anti-thyroid drugs: Two case reports and a literature review. Int J Clin Pharmacol Ther 2022; 60: 492-498
• 14 Duyff RF, Van den Bosch J, Laman DM. et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000; 68: 750-755
• 15 Cheng Y, Sun Z, Zhong D. et al. Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs. Medicine (Baltimore) 2020; 99: e22898
• 16 Nagayama Y, Tachibana S, Fukuda T. et al. Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease. Endocr J 2025; 72: 813-818
• 17 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452-458
• 18 Mizuno T, Suzuki N, Makino H. et al. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 2015; 137: 299-305
• 19 Hosojima H, Iwasaki R, Miyauchi E. et al. Rhabdomyolysis accompanying thyroid crisis: an autopsy case report. Intern Med (Tokyo, Japan) 1992; 31: 1233-1235
• 20 Cakir M, Mahsereci E, Altunbas H. et al. A case of rhabdomyolysis associated with thyrotoxicosis. J Natl Med Assoc 2005; 97: 732-734
• 21 Umezu T, Ashitani K, Toda T. et al. A patient who experienced thyroid storm complicated by rhabdomyolysis, deep vein thrombosis, and a silent pulmonary embolism: a case report. BMC Res Notes 2013; 6: 198
• 22 Silverman MB, Wray J, Bridwell RE. et al. Thyroid storm, rhabdomyolysis, and pulmonary embolism: an unusual triad case report. Clin Pract Cases Emerg Med 2020; 4: 540-543
• 23 Alshanti M, Eledrisi MS, Jones E. Rhabdomyolysis associated with hyperthyroidism. Am J Emerg Med 2001; 19: 317
• 24 Kim HR, Kim SH, Oh DJ. Rhabdomyolysis after a regular exercise session in a patient with Graves’ disease. Nephrology (Carlton) 2012; 17: 307-308
• 25 Summachiwakij S, Sachmechi I. Rhabdomyolysis induced by nonstrenuous exercise in a patient with graves’ disease. Case Rep Endocrinol. 2014: 286450
• 26 Lichtstein DM, Arteaga RB. Rhabdomyolysis associated with hyperthyroidism. Am J Med Sci 2006; 332: 103-105